RIPK1 and metabolic dysfunction-associated steatohepatitis: Taken together, results from our study uncover that NASH-associated UGDH reduction promotes RIPK1 activation due to reduced synthesis of UDP-GlcA, which contributes to the pathogenesis of NASH-associated liver damage through RIPK1 kinase-dependent hepatocyte apoptosis.